West Pharmaceutical Services Inc
NYSE:WST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (60.3), the stock would be worth $395.77 (34% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 45 | $295.36 |
0%
|
| 3-Year Average | 60.3 | $395.77 |
+34%
|
| 5-Year Average | 60.8 | $398.96 |
+35%
|
| Industry Average | 36.3 | $237.9 |
-19%
|
| Country Average | 23.2 | $152.31 |
-48%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
20.9B USD | 45 | 38.6 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 1 841 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.3B USD | 31.1 | 25.3 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.5B USD | 26.2 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 105.4 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
331.7B CNY | 24.7 | 16.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF | -164.7 | -119.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.5B USD | 33.3 | 24.4 | |
| US |
|
Waters Corp
NYSE:WAT
|
28.7B USD | 53.8 | 44.6 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.6B USD | 18.7 | 19.6 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.2B USD | 32.1 | 29 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.4 |
| Median | 23.2 |
| 70th Percentile | 35.1 |
| Max | 3 178 983.5 |
Other Multiples
West Pharmaceutical Services Inc
Glance View
Nestled in the heart of the pharmaceutical and healthcare industry is West Pharmaceutical Services Inc., a company that has woven itself into the fabric of drug delivery systems since its founding in 1923. This company, headquartered in Exton, Pennsylvania, operates with the precision of a Swiss watch, designing and manufacturing an array of cutting-edge containment and delivery solutions for injectable medicines. West's expertise is reflected in the products it develops—ranging from stoppers and seals for vials to advanced syringe and device technologies. Its robust research and development pipeline underscores a commitment to innovation, ensuring that new advances in drug delivery provide critical safety and efficacy for patients and healthcare professionals alike. West Pharmaceutical's business model revolves around partnering closely with pharmaceutical and biotechnology companies worldwide. This symbiotic relationship secures West's place at the forefront of global healthcare evolution. While the client companies focus on the complex process of drug formulation and therapeutic efficacy, West ensures that these drugs are delivered effectively and safely through its meticulously engineered components and systems. As a result, the company garners a revenue stream from a robust portfolio of products and services that cater to the long-term needs of its clients, helping them efficiently navigate the stringent regulatory environment. Through these partnerships and their resultant dividends, West Pharmaceutical Services continues to embed its name into the essential infrastructure of global health care.
